Shots:

• The approval is based on study assessing Asparlas (2500 U/m2- IV- q3w) in combination with multiagent chemotherapy in 124 patients with B-cell lineage ALL
• The study resulted in achievement and maintenance of nadir serum asparaginase activity above the level of 0.1 U/mL
• Asparlas (calaspargase pegol-mknl- IV) is an asparagine specific enzyme approved as a combination therapy for patients with ALL aged 1 month to 21 yr

Ref: The US FDA | Image: WSJ